Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
NCT00310635 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 241
Last updated 2006-10-26
Summary
Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Conditions
- Meningococcal Infection
Interventions
- BIOLOGICAL
-
Meningococcal C conjugate vaccine
Sponsors & Collaborators
-
Novartis Vaccines
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Vaccines - Information Services · Novartis Vaccines & Diagnostics
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 32 Months
- Max Age
- 40 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-06-30
Countries
- Germany
Study Locations
More Related Trials
-
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
NCT00667602 ·Status: COMPLETED ·Phase: PHASE3
-
Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine
NCT00310713 ·Status: COMPLETED ·Phase: PHASE4
-
Persistence of Immune Response After Vaccination With MCC
NCT00310687 ·Status: COMPLETED ·Phase: PHASE4
-
Kinetics of B Cell Response in Infants Menjugate Vaccination
NCT00310700 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
NCT00310817 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.
NCT00471081 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
NCT01434680 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
NCT00381615 ·Status: COMPLETED ·Phase: PHASE2
-
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
NCT01345721 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants
NCT00433914 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
NCT00806195 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
NCT00560313 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.
NCT01911221 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
NCT00196963 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
NCT01339923 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)
NCT00310856 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months
NCT05229536 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects
NCT01641042 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years
NCT00196950 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children
NCT00674583 ·Status: COMPLETED ·Phase: PHASE3
-
Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers
NCT03890367 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
NCT01148017 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
NCT00262002 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
NCT00721396 ·Status: COMPLETED ·Phase: PHASE2
-
Can we Reduce the Number of Vaccine Injections for Children?
NCT01129518 ·Status: COMPLETED ·Phase: PHASE4